Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’
Titel:
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’
Auteur:
Haas, M. Siveke, J.T. Schenk, M. Lerch, M.M. Caca, K. Freiberg-Richter, J. Fischer von Weikersthal, L. Kullmann, F. Reinacher-Schick, A. Fuchs, M. Kanzler, S. Kunzmann, V. Ettrich, T.J. Kruger, S. Westphalen, C.B. Held, S. Heinemann, V. Boeck, S.